Baseline Staging of Newly Diagnosed Prostate Cancer: A Summary of the Literature

Abuzallouf, S; Dayes, Ian; Lukka, Himu

doi:10.1097/01.ju.0000123981.03084.06

Cited by 236 publications

(140 citation statements)

References 54 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Bone scanning has been routinely used to detect bone metastases for patients with newly diagnosed prostate cancer (6). However, the detection rate of bone metastases in newly diagnosed prostate cancer is influenced by three major prognostic factors; PSA, stage and grade (12). Although the relationship between PSA and bone scan findings has been investigated, controversy exists as reports remain conflicting (12).…”

Section: Commentsmentioning

confidence: 99%

“…However, the detection rate of bone metastases in newly diagnosed prostate cancer is influenced by three major prognostic factors; PSA, stage and grade (12). Although the relationship between PSA and bone scan findings has been investigated, controversy exists as reports remain conflicting (12). Recent guidelines published by the National Institute for Clinical Excellence (NICE) (13) stated that bone scans are not required for staging purposes in prostate cancer with a PSA level of < 10 ng/mL where the Gleason score is < 8 and no bone pain is present, as there is a very low likelihood of detecting metastatic disease.…”

Section: Commentsmentioning

confidence: 99%

See 1 more Smart Citation

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study

et al. 2010

View full text Add to dashboard Cite

Purpose: Define a group of patients with newly diagnosed prostate cancer, whose risk of bone metastasis is low enough to omit a bone scan staging study. Materials and Methods: From 2003 to 2009, the medical records of patients who were newly diagnosed with prostate cancer were retrospectively reviewed. The data collected included: age, digital rectal examination, serum prostate specific antigen (PSA), Gleason score, clinical T stage, and bone isotope scan. Patients were divided into two groups according to the results of bone isotope scan; positive group and negative group. A univariate and multivariate binary logistic regression was used to analyze the results. Results: Of the 106 patients, 98 had a complete data collection and were entered into the study. The median age of the patients was 70.5 years and patients with a positive bone scan was 74 years, significantly higher than for patients with negative scans (69 years) (p = 0.02). Bone metastasis was detected in 39 cases (39.7%). In all patients with clinical T1-2 stage, a Gleason score of < 8 and PSA ≤ 20 ng/mL, the bone isotope scans were negative. In univariate analysis, PSA (> 20 ng/mL) and Gleason score (> 7) were independently predictive of positive bone scan, while clinical stage was not. Conclusion: Staging bone scans can be omitted in patients with a PSA level of ≤ 20 ng/mL, and Gleason score < 8. Our results suggest that by considering the Gleason score and PSA, a larger proportion of patients with prostate cancer could avoid a staging bone scan.

show abstract

Section: Commentsmentioning

confidence: 99%

Section: Commentsmentioning

confidence: 99%

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…suggested that bone scan should be done only in selective high risk patients (Oesterling et al, 1993;Lee et al, 2000;Abuzallouf et al, 2004;Hirobe et al, 2007). However, in another study, it has been suggested that bone scan should be used in all patients as there is a lack of reliable marker to identify high risk patients (Wolff et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases

Seong

Zainuddin³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Comparativamente com outras modalidades imagiológicas, como a tomografia computorizada (CT) e a ressonância magnética (RM), emerge como uma técnica capaz de identificar lesões, independentemente de critérios dimensionais, traduzindo-se em maior precocidade e sensibilidade na sua detecção. 17,18 A colina é um percursor na biossíntese dos fosfolípidos da membrana celular. É incorporada no meio intracelular através de um transportador específico e utilizada na síntese de fosfatidilcolina.…”

unclassified

PET/CT com Fluorocolina-F18 em Doentes com Carcinoma da Próstata em Recidiva Bioquímica

et al. 2016

View full text Add to dashboard Cite

Results:The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-Fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-Fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy. Keywords: Fluorocholine; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals. INTRODUÇÃOO carcinoma da próstata (CaP) é, na Europa, a neoplasia maligna mais comum no sexo masculino e a segunda causa de morte por cancro, tendo-se assistido a um aumento significativo da sua incidência nas últimas décadas. 1Uma vez que a idade é um factor de risco bem estabelecido no CaP prevê-se que, com o aumento da esperança média de vida, esta doença se torne num problema de saúde pú-blica, cada vez mais relevante. 2Após a terapêutica com intuito curativo, o seguimento destes doentes baseia-se, sobretudo, no doseamento sé-rico do antigénio específico da próstata (PSA) e a recidiva bioquímica é um acontecimento relativamente frequente. Terapêuticas de salvação são reservadas para doentes com recidiva loco regional. Nos doentes com metastização à distância, o tratamento paliativo mais comum é a Terapêutica de Supressão Hormonal (TSH). 4 Contudo, tem-se assistido a uma progressão das terapêuticas disponíveis, com introdução de terapias individualizadas.

show abstract

Baseline Staging of Newly Diagnosed Prostate Cancer: A Summary of the Literature

Cited by 236 publications

References 54 publications

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study

Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases

PET/CT com Fluorocolina-F18 em Doentes com Carcinoma da Próstata em Recidiva Bioquímica

Contact Info

Product

Resources

About